By proceeding, you agree to our Terms of Use and Privacy Policy.
Arthur M. Krieg, MD has worked in the oligonucleotide field since the 1980s. Most recently he founded Checkmate Pharmaceuticals to develop novel oligonucleotides for cancer immunotherapy.
Talks About #Pharmaceuticals
Preferred Locations #NorthAmerica
The 3rd TLR & PRR-Targeted Therapies Summit is coming at a timely inflection point in this field.
The STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field.
